Comparing Dapagliflozin and Glimepiride in treating patients with type 2 Diabetes.

To compare the safety and efficacy of Dapagliflozin and Glimepiride as add-on to Metformin in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220408054450N1

Enrollment

200

Registered

2022-09-11

Start date

2019-10-15

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus. Type 2 Diabetes

Interventions

Intervention 1: Intervention group 1: Glimepiride (4mg) once daily and Metformin (500mg) three times a day orally for 12 weeks. Intervention 2: Intervention group 2: Dapagliflozin (10mg) once daily a

Eligibility

Sex/Gender

All

Age

45 Years to 55 Years

Inclusion criteria

Inclusion criteria: normal baseline levels of LFT, RFT, lipid profile, and white blood cell count (WBC). The fasting plasma glucose (FBG) levels of all recruited participants to be = 126 mg/dL hemoglobin A1c levels to be >7-10% 1500 mg/day metformin monotherapy for last 3 to 6 months. Age of 45-55 years old Either gender

Exclusion criteria

Exclusion criteria: Hypertension Decompensated or acute congestive heart failure Estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73 m2 Left ventricular ejection fraction (levf) less than 40% Liver impairment Terminal illness, or cancer Unwilling to give consent or participate

Design outcomes

Primary

Measure	Time frame
Hemoglobin A1c (HbA1c) - Glycelated hemoglobin. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using analyser in laboratory.;Fasting Plasma Glucose (FPG). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using device for plasma blood glucose.	—

Measure

Time frame

Hemoglobin A1c (HbA1c) - Glycelated hemoglobin. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using analyser in laboratory.;Fasting Plasma Glucose (FPG). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using device for plasma blood glucose.

—

Secondary

Measure	Time frame
Liver Function Test. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Renal Function Test (RFT). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Lipid Profile. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Hypoglycemic Events. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Through fasting Plasma glucose levels and medical history.	—

Measure

Time frame

Liver Function Test. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Renal Function Test (RFT). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Lipid Profile. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Hypoglycemic Events. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Through fasting Plasma glucose levels and medical history.

—

Countries

Pakistan

Contacts

Public ContactMuhammad Kamran Yousuf

Bahria University Medical & Dental College, Karachi

kmran2010@gmail.com+92 333 9800961

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026